Efficacy and Safety Study of Imprime PGG With Cetuximab in Subjects With Stage IV KRAS-Mutated Colorectal Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Leonard Saltz, MD
Memorial Sloane-Kettering Cancer Center
Principal Investigator - Neil H. Segal, MD, PhD
Memorial Sloane-Kettering Cancer Center
Principal Investigator - Neil Senzer, MD
Mary Crowley Medical Research Center
Principal Investigator - Purvi Gada, MD
University of Minnesota
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of Minnesota
Minneapolis, Minnesota, United States
- Memorial Sloane-Kettering Cancer Research Center
New York, New York, United States
- Mary Crowley Medical Research Center
Dallas, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Jun 2009
- Primary completion
- 29 Feb 2012
- Completion
- 29 Feb 2012
- Last update posted
- 15 Feb 2012
- Registered enrollment
- 18
- Registry id
- NCT00912327
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.